



**PRANEETH REDDY SUDALAGUNTA**

[PraneethReddy.Sudalagunta@moffitt.org](mailto:PraneethReddy.Sudalagunta@moffitt.org)

<https://www.praneeth.info/>

**Phone: (540)998-9970**

[Google Scholar Page](#)

ORCID: [0000-0003-1283-9332](https://orcid.org/0000-0003-1283-9332)

**Research Vision:** To contribute to making *personalized medicine* a reality in the clinic, specifically using *predictive biomarkers* informed by cancer patients' clinical response to individual treatments contextualized by molecular and pathological features of their tumor and its microenvironment. This would involve integrating clinical, demographic, imaging, molecular, and experimental features via novel methodologies relying on statistical methods, machine learning techniques, and mathematical models. Such a research endeavor would require curating a comprehensive relational database linking clinical and operational data elements with experimental and molecular features, thereby advancing the *bench-to bedside* revolution in cancer care.

<b>EDUCATION &amp; TRAINING:</b>	<ul style="list-style-type: none"> <li>➤ <b>Applied Research Scientist I</b> (September 2021 – present), Department of Cancer Physiology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL.</li> <li>➤ <b>Applied Postdoctoral Fellow</b> (May 2018 – August 2021), Department of Cancer Physiology, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL.</li> <li>➤ <b>Postdoctoral Fellow</b> (September 2016 – April 2018), Department of Cancer Imaging and Metabolism, H. Lee Moffitt Cancer Center &amp; Research Institute, Tampa, FL.</li> <li>➤ <b>PhD in Aerospace Engineering</b> (2012 – 2016), Virginia Polytechnic Institute and State University, Blacksburg, VA. <b>GPA 3.96/4</b></li> <li>➤ <b>Master of Technology in Aerospace Engineering</b> (2010 – 2012), Indian Institute of Technology Kanpur, Kanpur, India. <b>GPA 9.5/10</b></li> <li>➤ <b>Bachelor of Technology in Electrical and Electronics Engineering</b> (2006 – 2010), Jawaharlal Nehru Technological University Hyderabad, Hyderabad, India.</li> </ul>
<b>RESEARCH GRANTS &amp; FUNDING:</b>	<ul style="list-style-type: none"> <li>❖ <b>2022 Research Instructor (20% FTE)</b> Intramural support of 20% FTE to help carve out independent research projects to aid in career advancement for successful postdoctoral fellows and research scientists at Moffitt Cancer Center.</li> <li>❖ <b>2022 NCI-IBM IDEAS Lab for Biologically Informed Combination Therapies (\$100,000 - Awarded but not Funded)</b> Title: <i>A Framework for Identifying Biologically-Informed Combination Therapy Dosing and Therapeutic Repurposing in Pancreatic Cancer.</i> Role: <u>Co-PI</u> with Dr. Tero Aittokallio (University of Helsinki, Finland), Dr. David Hormuth (University of Texas-Austin), and Dr. Jeremy Kratz (University of Wisconsin-Madison).</li> <li>❖ <b>2021 MMRF (Multiple Myeloma Research Foundation) Research Fellow Award (\$75,000)</b> Title: <i>A Multiomic Approach to Reverse Therapy Resistance in Multiple Myeloma.</i> Role: <u>Principal Investigator</u>. 12/01/2021 – 12/31/2022.</li> <li>❖ <b>2019 Moffitt PSOC (Physical Sciences – Oncology Center) Pilot Project Award (\$15,000)</b> Title: <i>Ex Vivo Dynamical Modeling of Multiple Myeloma using Individual Cell Tracking.</i> Role: <u>Principal Investigator</u>. 01/01/2020 – 08/31/2020.</li> <li>❖ <b>2018 Moffitt PSOC (Physical Sciences – Oncology Center) Pilot Project Award (\$16,600)</b> Title: <i>An ODE-based Mathematical Model of Multiple Myeloma Cell Dynamics ex vivo.</i> Role: <u>Principal Investigator</u>. 01/01/2019 – 08/31/2019.</li> </ul>
<b>PATENTS:</b>	<ul style="list-style-type: none"> <li>➤ Silva, A., Shain, K., <b>Sudalagunta, P.R.</b>, Canevarolo, R., Meads, M., “<a href="#">A model of clinical synergy in cancer</a>”, PCT/US2020/062232 (WO/2021/108551-A1), priority date 11/25/2019.</li> <li>➤ Silva, A., <b>Sudalagunta, P.R.</b>, Shain, K., Canevarolo, R., Meads, M., “<a href="#">A Multiomic Approach to Modeling of Gene Regulatory Networks in Multiple Myeloma</a>”, PCT/US2022/024217 (WO/2022/217136-A1), priority date 04/10/2021.</li> <li>➤ Silva, A., Shain, K., Canevarolo, R., <b>Sudalagunta, P.R.</b>, Meads, M., “<a href="#">Altering Epigenetic Landscapes Control Progression And Refractory Disease States In Multiple Myeloma</a>”, US Provisional Application No. 63/422,106, priority date 11/03/2022.</li> </ul>

<p><b>FEATURED IN MEDIA</b></p>	<ul style="list-style-type: none"> <li>• <b>The Patient Story</b> (March 1<sup>st</sup>, 2022): <a href="https://www.thepatientstory.com/research/multiple-myeloma-research/daratumumab-selinexor-moffitt/">https://www.thepatientstory.com/research/multiple-myeloma-research/daratumumab-selinexor-moffitt/</a></li> <li>• <b>Moffitt Endeavor</b> (February 4<sup>th</sup>, 2021): <a href="https://moffitt.org/endeavor/archive/combining-cycling-people-and-a-passion-for-cancer-research">https://moffitt.org/endeavor/archive/combining-cycling-people-and-a-passion-for-cancer-research</a></li> </ul>
<p><b>DATA SCIENCE &amp; TECHNOLOGY CONTRIBUTIONS</b></p> <p>(CONCEPTION, DESIGN, DEVELOPMENT, AND DEPLOYMENT)</p>	<ul style="list-style-type: none"> <li>❖ <b>Automated Monitoring and Analysis of Ex Vivo Drug Sensitivity Assays:</b> Total Cancer Care® (TCC) consented Multiple myeloma (MM) patient samples at Pentecost Myeloma Research Center (PMRC) are treated with 31 drugs in ex vivo co-cultures and live imaged for six days. These experiments are programmatically monitored by a code continuously running on a HPC, which inspects the image metadata and flags any experimental issues by sending automated text messages to members of PMRC lab. This code also automatically analyzes the images once the experiment is completed and generates a PDF report summarizing the experimental results. Currently, these reports are forwarded to MM physicians at Moffitt to aid in clinical decision making.</li> <li>❖ <b>REDCap Project to Track Sequential Biopsies Assayed at PMRC:</b> PMRC lab receives over 250 TCC-consented MM patient samples each year, this REDCap project is actively used to link sequential biopsies from a given patient and their respective clinical progression status along with list of drugs tested ex vivo and LIMS sample IDs for future use.</li> <li>❖ <b>Abstraction of MM Patient Treatment History from MCAP Billing Codes:</b> MM patient samples collected by PMRC lab (so far ~1100) require to be contextualized by their treatment histories to aid in further analyses. This was done by programmatically pulling MM patients' drugs, their dose, and billing dates from billing codes in Moffitt Cancer Analytics Platform (MCAP) to programmatically abstract MM patient treatment histories. The only alternative is manually abstracted data from NTRO (Non-therapeutic Research Office).</li> <li>❖ <b>Abstraction of MM Patient Response History from MCAP Labs Data:</b> Molecular and ex vivo data from PMRC samples (~1100) need response stratification for each line of treatment received by the patient. This is programmatically calculated using MCAP serum labs data and IMWG (International Myeloma Working Group) criteria for response stratification. The only alternative is manually abstracted data from NTRO (Non-therapeutic Research Office).</li> <li>❖ <b>Abstraction of MM Patient Cytogenetic Status from FISH Pathology Reports:</b> MM samples in the clinic are subjected to FISH (Fluorescence In-situ Hybridization) to characterize the patient's risk using their cytogenetic status. The data available on MCAP for this only involves six cytogenetic abnormalities abstracted and available for querying, while there is a free text field from the pathology report providing additional details that is programmatically abstracted into 21 cytogenetic abnormalities (using the same FISH probes) and quantifying the percent cells with the abnormality, which provides valuable information on tumor clonality.</li> <li>❖ <b>PMRC Relational Database Linking Clinical, Molecular, and Experimental Data:</b> The disparate data elements for each of ~1100 MM samples collected by PMRC lab are integrated to link molecular profiling by RNA and whole exome sequencing paired with ex vivo drug response, clinical disease status, cytogenetic status, treatment history, and clinical response for each patient to facilitate translational research.</li> </ul>
<p><b>INVITED TALKS/ CONFERENCES</b></p>	<ul style="list-style-type: none"> <li>→ <b>Sudalagunta, P. R.</b>, "Functional Genomic Landscape of Multiple Myeloma Identifies Novel Therapeutic Strategies", <b>2022 Moffitt Scientific Symposium</b>, Tampa, Florida, 2022.</li> <li>→ <b>Sudalagunta, P. R.</b>, "Functional Genomic Landscape of Multiple Myeloma Informed by TCC-Avatar Data Identifies Novel Therapeutic Strategies", <b>2022 ORIEN Scientific Retreat</b>, Saint Petersburg, Florida, 2022.</li> <li>→ <b>Sudalagunta, P. R.</b>, "<a href="#">Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq</a>", <b>2021 American Society of Hematology Annual Meeting</b>, Atlanta, Georgia, 2021.</li> <li>→ <b>Sudalagunta, P. R.</b>, "<a href="#">Aeroelastic Control-oriented Modeling of an Air-breathing Hypersonic Vehicle</a>," <b>15<sup>th</sup> Dynamics Specialists Conference, AIAA Science and Technology Forum and Exposition</b>, San Diego, California, 2016.</li> <li>→ <b>Sudalagunta, P. R.</b>, "<a href="#">A Novel Scheme to Accurately Compute Higher Vibration Modes using the Ritz Method and a Two-point BVP Solver</a>," <b>56<sup>th</sup> AIAA/ASCE/AHS/ASC Structures, Structural Dynamics, and Materials Conference</b>, Kissimmee, Florida, 2015.</li> </ul>

<p style="text-align: center;"><b>AWARD-WINNING ABSTRACTS:</b></p>	<p>→ <b>[Abstract Achievement Award]</b> Sudalagunta, P. R., Canevarolo, R. R., Meads, M. B., Silva, M. C., Cubitt, C, De Avila, G., Alugubelli, R. R., Logothetis, C., Zhang, Q., Hampton, O., DeCastro, A., Van Domelen, D. R., Chai, Y., Walker, C. J., Silva, A. S., Landesman, Y., Baz, R., and Shain, K. H. “Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq”, <b>ASH Annual Meeting</b>, December 2021, <i>Blood</i>.</p> <p>→ <b>[Abstract Achievement Award]</b> Sudalagunta, P. R., Renatino Canevarolo, R., Coelho Siqueira Silva, M. D., Meads, M. B., Tungesvik, A., De Avila, G., Shain, K. H., &amp; Siqueira Silva, A., “Pharmacodynamical Modeling of Two-Way Synergistic Effect for High-Throughput Drug Combination Screening in an Ex Vivo Reconstruction of Bone Marrow Using Primary Multiple Myeloma Cells”, <b>ASH Annual Meeting</b>, December 2018, <i>Blood</i>, 132(Suppl 1), 1919.</p> <p>→ <b>[Best Poster Award]</b> Sudalagunta, P. R., Renatino Canevarolo, R., Coelho Siqueira Silva, M. D., Meads, M. B., De Avila, G., Nguyen, T., Cubitt, C., Baz, R., Dalton, W., Shain, K., Silva, A., “Mechanistic Modeling of Response to Therapy in Multiple Myeloma from ex vivo Measurements”, <b>2017 Physical Sciences - Oncology Network Annual Investigators Meeting</b>, MIT, October 2017.</p> <p>→ <b>[Young Investigator Award for Outstanding Poster]</b> Sudalagunta, P. R., Renatino Canevarolo, R., Coelho Siqueira Silva, M. D., Meads, M. B., De Avila, G., Nguyen, T., Cubitt, C., Baz, R., Dalton, W., Shain, K., Silva, A., “Mechanistic Modeling of Response to Therapy in Multiple Myeloma from ex vivo Measurements”, <b>Frontiers in Biomedical Imaging Science VI</b>, Vanderbilt University Institute of Imaging Sciences (VUIIS), May 2017.</p> <p>→ <b>[Best Poster Award]</b> Sudalagunta, P. R., Renatino Canevarolo, R., Coelho Siqueira Silva, M. D., Meads, M. B., De Avila, G., Nguyen, T., Cubitt, C., Baz, R., Dalton, W., Shain, K., Silva, A., “Mechanistic Modeling of Response to Therapy in Multiple Myeloma from ex vivo Measurements”, <b>Moffitt Scientific Symposium</b>, May 2017.</p>
<p style="text-align: center;"><b>RESEARCH MENTORSHIP:</b></p>	<p>➤ <b>Qibing Jiang</b> (Fall, 2019 – present), Department of Computer Science, University of Central Florida, Orlando, FL (Co-mentored with Dr. Wei Zhang)</p> <ul style="list-style-type: none"> <li>○ Developed a comprehensive digital image processing tool in Python to dynamically quantify live imaging data of multiple myeloma cells extracted from bone marrow specimens donated by patients at Moffitt Cancer Center.</li> </ul> <p>➤ <b>High School Internship Program – Integrated Mathematical Oncology</b>, Moffitt Cancer Center &amp; Research Institute, Tampa, FL.</p> <p><b>Jonathan Williams</b> (Summer, 2019), Pine Crest Preparatory School, Fort Lauderdale, FL</p> <ul style="list-style-type: none"> <li>○ Reconstructed concentration-time curves using a pharmacokinetic model for an orally administered drug (Panobinostat) from parameters estimated in phase I clinical trials. Showed that dose modulation can benefit partially responding multiple myeloma (MM) patients, reinforcing the need for personalized medicine tools.</li> </ul> <p><b>Daniel Newton</b> (Summer, 2018), San Marcos High School, Santa Barbara, CA</p> <ul style="list-style-type: none"> <li>○ Developed an ODE model for MM cell line growth by fitting first and second order growth rates of MM cell populations (as opposed to cell population measures) in an <i>ex vivo</i> reconstruction of the bone marrow. Instrumental in PSOC pilot project award. Currently, an undergraduate student at Harvard.</li> </ul> <p><b>Urvashi Mahajan</b> (Summer, 2017), C. Leon King High School, Tampa, FL</p> <ul style="list-style-type: none"> <li>○ Simulated adaptive therapy for Bortezomib monotherapy using patient-specific models in multiple myeloma (MM), informed by experiments conducted on patient-derived MM cells in an <i>ex vivo</i> reconstruction of the bone marrow.</li> </ul>
<p style="text-align: center;"><b>ACADEMIC AWARDS:</b></p>	<ul style="list-style-type: none"> <li>▪ <b>2022 Research Instructor</b>, H. Lee Moffitt Cancer Center &amp; Research Institute.</li> <li>▪ <b>2021 MMRF (Multiple Myeloma Research Foundation) Research Fellow Award</b>.</li> <li>▪ <b>Abstract Achievement Award</b>, American Society of Hematology, ASH Annual Meeting, 2021.</li> <li>▪ <b>Moffitt Physical Sciences – Oncology Center Pilot Project Award – 2019</b>.</li> <li>▪ <b>Abstract Achievement Award</b>, American Society of Hematology, ASH Annual Meeting, 2018.</li> <li>▪ <b>Moffitt Physical Sciences – Oncology Center Pilot Project Award – 2018</b>.</li> <li>▪ <b>Two Minute Elevator Pitch Contest Winner</b>, Developing Clinical Decision Support Tools in Multiple Myeloma, Junior Scientists Retreat, USF, 2018.</li> <li>▪ <b>Best Poster Award</b>, Novel Quantitative Methods, 2017 Physical Sciences - Oncology Network Annual Investigators Meeting, MIT, October 2017.</li> <li>▪ <b>Young Investigator Award for Outstanding Poster</b>, Frontiers in Biomedical Imaging Science VI, Vanderbilt University Institute of Imaging Sciences (VUIIS), May 2017.</li> </ul>

	<ul style="list-style-type: none"> <li>▪ <b>Best Poster Award</b>, Clinical Science Division, Moffitt Scientific Symposium, May 2017.</li> <li>▪ <b>Academic Excellence Award</b> in Aerospace Engineering from Indian Institute of Technology Kanpur for the year 2010 – 2011.</li> <li>▪ Secured All India Rank (AIR) 94 in GATE-2010 (Graduate Aptitude Test in Engineering) and 102 in GATE-2009, Electrical &amp; Electronics Engineering.</li> </ul>
<b>FIRST-AUTHORED JOURNAL PUBLICATIONS:</b>	<ol style="list-style-type: none"> <li>1. <b>Sudalagunta, P. R.</b>, Canevarolo, R. R., Meads, M. B., Silva, M. C., Zhao, X., Cubitt, C., Sansil, S., De Avila, G., Alugubelli, R. R., Bishop, R., Logothetis, C., Tungesvik, A., Zhang, Q., Hampton, O., Teer, J., Welsh, E., Yoder, S., Shah, B., Hazelhurst, L., Perez, L., Gatenby, R., Van Domelen, D. R., Chai, Y., Wang, F., DeCastro, A., Bloomer, A. M., Siegel, E. M., Lynch, C., Sullivan, D., Alsina, M., Nishihori, T., Brayer, J., Cleveland, J., Dalton, W., Walker, C., Landesman, Y., Baz, R., Shain, K. H., Silva, A., "<a href="#">Functional Transcriptomic Landscape Informs Novel Therapeutic Strategies in Multiple Myeloma</a>," <i>Blood Cancer Discovery</i> (revised manuscript pending resubmission).</li> <li>2. <b>Sudalagunta, P. R.</b>, Silva, M. C., Canevarolo, R. R., Alugubelli, R. R., De Avila, G., Tungesvik, A., Perez, L., Gatenby, R., Gillies, R., Meads, M. B., Shain, K. H., Silva, A., "<a href="#">Pharmacodynamic Model of Clinical Synergy in Multiple Myeloma</a>," <i>eBioMedicine</i>, 2020, 102716.</li> <li>3. <b>Sudalagunta, P. R.</b>, Sultan, C., Kapania, R., Watson, L. W., and Raj, P., "<a href="#">Aeroelastic Control-oriented Modeling of an Air-breathing Hypersonic Vehicle</a>," <i>AIAA Journal of Guidance, Control, and Dynamics</i>, Vol. 41, No. 5 (2018), pp. 1136 – 1149.</li> <li>4. <b>Sudalagunta, P. R.</b>, Sultan, C., Kapania, R., Watson, L. W., and Raj, P., "<a href="#">Accurate Computing of Higher Vibration Modes of Thin Flexible Structures</a>," <i>AIAA Journal</i>, Vol. 54, No. 5 (2016), pp. 1704 – 1718.</li> </ol>
<b>MENTORED PUBLICATIONS:</b>	<ol style="list-style-type: none"> <li>5. Jiang, Q., <b>Sudalagunta, P. R.</b>, Silva, M. C., Canevarolo, R. R., Alugubelli, R. R., De Avila, G., Tungesvik, A., Perez, L., Gatenby, R., Gillies, R., Meads, M. B., Shain, K. H., Silva, A., Zhang, W., "<a href="#">CancerCellTracker: A Brightfield Time-lapse Microscopy Framework for Cancer Drug Sensitivity Estimation</a>," <i>Bioinformatics</i>, Vol. 38, No. 16 (2022), pp. 4002 – 4010.</li> </ol>
<b>CO-AUTHORED JOURNAL PUBLICATIONS:</b>	<ol style="list-style-type: none"> <li>6. Tauro, M., Li, T., <b>Sudalagunta, P. R.</b>, Meads, M., Alugubelli, R., Lawrence, N. J., Lawrence, H., Gunawan, S., Tran, T. H., Shay, G., Schonbrunn, E., Bishop, R. T., Nasr, M., Cleveland, J. L., Silva, A. S., Shain, K. H., Lynch, C. <u>Unc-51 Like Kinase 3 (ULK3) is a novel mediator of autophagy and cell viability in multiple myeloma.</u> <b>Cancer Cell</b> (To be submitted shortly).</li> <li>7. Bishop, R. T., Li, T., <b>Sudalagunta, P. R.</b>, Nasr, M., Nyman, K., Alugubelli, R., Meads, M., Frieling, J., Nerlakanti, N., Tauro, M., Fang, B., Grant, S., Koomen, J., Silva, A., Shain, K. H., Lynch, C., <u>Acid Ceramidase (ASAH1) controls proteasome inhibitor resistance and is a tractable target for relapsed/refractory multiple myeloma.</u> <b>The Journal of Experimental Medicine</b> (Currently under review).</li> <li>8. Bishop, R. T., Miller, A. K., Froid, M., Nerlakanti, N., Li, T., Frieling, J., Nasr, M., Nyman, K., <b>Sudalagunta, P. R.</b>, Canevarolo, R. R., Silva, A. S., Shain, K. H., Lynch, C., Basanta, D. <u>The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous proteasome inhibitor resistant disease.</u> <b>Nature Communications</b> (Revised manuscript resubmitted)</li> <li>9. Canevarolo RR, Meads M, Silva MCS, <b>Sudalagunta, P. R.</b>, DeAvila G, Alugubelli RR, Tungesvik A, Bell ET, Burger K, Kulkarni A, Hampton O, Jiang Z, Dai H, Cubitt C, Teer J, Welsh E, Yoder S, Shah B, Tao J, Hazlehurst L, Gatenby R, Sullivan D, Alsina M, Nishihori T, Brayer J, Cleveland JL, Dalton W, Gillies RJ, Baz R, Shain KH, Silva AS. <a href="#">Dynamic super-enhancer core regulatory circuits and epigenetic landscapes drive malignant progression and refractory disease in multiple myeloma</a>. Pre-print DOI: 10.21203/rs.3.rs-125536/v1 (To be submitted to <b>Blood Cancer Discovery</b> shortly).</li> <li>10. Burger K, Fernandez M, Meads MB, <b>Sudalagunta P.R.</b>, Oliveira P, Canevarolo RR, Alugubelli RR, Tungesvik A, Avila G, Silva M, Graeter A, Dai H, Vinceletti N, Prabhu A, Magaletti D, Yang C, Li W, Kulkarni A, Hampton O, Koomen J, Roush W, Monastyrskyi A, Berglund A, Silva AS, Cleveland J, Shain KH. <a href="#">CK1δ/CK1ε Signaling Sustains Mitochondrial Metabolism and Cell Survival in Multiple Myeloma.</a> <b>Cancer Research</b> 2023.</li> </ol>

11. Mostofa, A. G. M., Distler, A., Meads, M. B., Sahakian, E., Powers, J. J., Achille, A., Noyes, D., Wright, G., Fang, B., Izumi, V., Koomen, J., Ramakrishnan R., Nguyen, T. P., De Avila, G., Silva, A. S., **Sudalagunta, P.**, Canevarolo, R. R., Silva, M. C., Alugubelli, R. R., Dai, H. A., Kulkarni, A., Dalton, W. S., Hampton, O. A., Welsh, E. A., Teer, J. K., Tungesvik, A., Wright, K. L., Pinilla-Ibarz, J., Sotomayor, E. M., Shain, K. H., and Brayer, J., "[Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma](#)". *JCI Insight*, Volume 6, Issue 24, 2021. DOI: 10.1172/jci.insight.151713.
12. Zhou, L., Zhang, Y., Meads, M. B., Dai, Y., Ning, Y., Hu, X., Li, L., Sharma, K., Nkwocha, J., Parker, R., Bui D., McCarter, J., Kramer, L., Purcell, C., **Sudalagunta, P. R.**, Canevarolo, R. R., Silva, M. C., DeAvila, G., Alugubelli, R. R., Silva, A. S., Kmiecik, M., Ferreira-Gonzalez, A., Shain, K. H., Grant, S, "[IAP and HDAC inhibitors interact synergistically in myeloma cells through noncanonical NF- \$\kappa\$ B- and caspase-8-dependent mechanisms](#)". *Blood Adv* 2021, Volume 5, Issue 19, pp. 3776–3788. DOI: 10.1182/bloodadvances.2020003597.
13. Zhao, X., Ren, Y., Lawlor, M., Shah, B. D., Park, P. M. C., Lwin, T., Wang, X., Liu, K., Wang, M., Gao, Jing., Li, T., Xu, M., Silva, A. S., Lee, K., Zhang, T., Koomen, J. M., Jiang, H., **Sudalagunta, P. R.**, Meads, M. B., Cheng, F., Bi, C., Fu, K., Fan, H., Dalton, W., Moscinski, L., Shain, K. H., Sotomayor, E., Wang, G. G., Gray, N. S., Cleveland, J. L., Qi, J., Tao, J., "[BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models](#)", *Cancer Cell*, Volume 35, Issue 5, 2019, pp. 752 – 766.
14. Ren, Y., Bi, C., Zhao, X., Lwin, T., Wang, C., Yuan, J., Silva, A. S., Shah, B. D., Fang, B., Li, T., Koomen, J., Jiang, H., Chavez, J., Pham, L., **Sudalagunta, P. R.**, Wan, L., Wang, X., Dalton, W., Moscinski, L., Shain, K. H., Vose, J., Cleveland, J. L., Sotomayor, E., Fu, K., Tao, J., "[PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas](#)", *Journal of Clinical Investigation*, Vol. 128, No. 12 (2018), pp. 5517 – 5530.
15. Silva, A., Silva, M. C., **Sudalagunta P.**, Distler, A., Jacobson, T., Collins, A., Nguyen, T., Song, T., Chen, D., Chen, L., Cubitt C., Baz, R., Perez, L., Rebatchouk, D., Dalton, W., Greene, J., Gatenby, R., Gillies, R., Sontag, E., Meads, M. B., and Shain, K. H., "[An Ex Vivo Platform for the Prediction of Clinical Response in Multiple Myeloma](#)", *Cancer Research*, Vol. 77, No. 12 (2017), pp. 3336 – 3351.

**SERVICE  
ACTIVITIES:**

- **EDITORIAL:** Reviewed 21 publications. See [Peer Review Profile](#)
  - ❖ Editorial Board Member, *Frontiers in Pharmacology & Frontiers in Bioinformatics*
  - ❖ Reviewer, *IEEE Transactions on Automatic Control* 2019
  - ❖ Reviewer, *Nonlinear Dynamics* 2018
  - ❖ Reviewer, *AIAA Journal* 2016 – 2017
  - ❖ Reviewer, *IEEE Transactions on Intelligent Transportation Systems* 2015 – 2016, 2019
  - ❖ Reviewer, *American Control Conference* 2014 – 2017
  - ❖ Reviewer, *IEEE Conference on Decision and Control* 2017 & 2019
  - ❖ Reviewer, *ASME Dynamic Systems and Control Conference* 2015 – 2016
- **Planning Committee Member**, NCI Physical Sciences-Oncology Network ([PS-ON](#)) and Cancer Systems Biology Consortium ([CSBC](#)) Annual Junior Investigator (JI) Meeting 2019.
- **COMMUNITY SERVICE:**
  - ❖ Hospice Volunteer, LifePath Hospice – Chapters Health System, Tampa, FL (2017 – 2019)
    - Provide companionship to patients under end-of-life hospice care by making weekly visits to a nursing home.
  - ❖ Para-professional Phone Counsellor, RAFT Crisis Hotline, New River Valley Community Services (2015 – 2016)
    - Certified to provide Mental Health First Aid
    - **Volunteer of the Month Award: January 2016 & Life Saver Award, 2016**
- **SERVICE @ MOFFITT:**
  - ❖ Service Committee Chair (2019 – 2020), Moffitt Postdoctoral Association, Moffitt Cancer Center & Research Institute, Tampa, FL.
  - ❖ Biked 325 miles on a bicycle from Tampa to Tallahassee for annual Moffitt Day 2019 – 2021 at the Florida State Capitol to advocate for continued support towards cancer research from the state of Florida.
  - ❖ Captain for the Moffitt Postdoctoral Team – TUMORBUSTERS, which raised over 5000\$ for 2019 Miles for Moffitt. Top 25 highest fundraising teams.
  - ❖ Volunteered at the St. Petersburg Science Festival (2017 & 2018)

<b>REFERENCES:</b>	<p>→ <b>Dr. Ariosto Silva, PhD</b> Associate Member, Cancer Physiology, Moffitt Cancer Center Email: <a href="mailto:Ariosto.Silva@moffitt.org">Ariosto.Silva@moffitt.org</a> Ph: (813) 745-8205</p> <p>→ <b>Dr. Ken Shain, MD, PhD</b> Associate Member &amp; Co-director PMRC, Malignant Hematology, Moffitt Cancer Center Email: <a href="mailto:Ken.Shain@moffitt.org">Ken.Shain@moffitt.org</a> Ph: (813) 745-3907</p> <p>→ <b>Dr. Rachid Baz, MD</b> Senior Member &amp; Co-director PMRC, Malignant Hematology, Moffitt Cancer Center Email: <a href="mailto:Rachid.Baz@moffitt.org">Rachid.Baz@moffitt.org</a> Ph: (813) 745-8212</p>
--------------------	---